Improving Corneal Permeability of Dexamethasone Using Penetration Enhancing Agents: First Step Towards Achieving Topical Drug Delivery to the Retina

UDC.coleccionInvestigación
UDC.departamentoQuímica
UDC.grupoInvNanochemistry and Self-Assembly for Biological Sciences (NANOSELF4BIO)
UDC.institutoCentroCICA - Centro Interdisciplinar de Química e Bioloxía
UDC.journalTitleInternational Journal of Pharmaceutics
UDC.startPage124305
UDC.volume660
dc.contributor.authorThareja, Abhinav
dc.contributor.authorLeigh, Thomas
dc.contributor.authorHakkarainen, Jenni J.
dc.contributor.authorHughes, Helen
dc.contributor.authorÁlvarez-Lorenzo, Carmen
dc.contributor.authorBlanch, Richard J.
dc.contributor.authorFernández-Trillo, Paco
dc.contributor.authorAhmed, Zubair
dc.date.accessioned2026-11-18T19:53:12Z
dc.date.available2026-11-18T19:53:12Z
dc.date.issued2024-06-07
dc.description.abstract[Abstract] With an ever-increasing burden of vision loss caused by diseases of the posterior ocular segment, there is an unmet clinical need for non-invasive treatment strategies. Topical drug application using eye drops suffers from low to negligible bioavailability to the posterior segment as a result of static and dynamic defensive ocular barriers to penetration, while invasive delivery systems are expensive to administer and suffer potentially severe complications. As the cornea is the main anatomical barrier to uptake of topically applied drugs from the ocular surface, we present an approach to increase corneal permeability of a corticosteroid, dexamethasone sodium-phosphate (DSP), using a novel penetration enhancing agent (PEA). We synthesised a novel polyacetylene (pAc) polymer and compared its activity to two previously described cell penetrating peptide (CPP) based PEAs, TAT and penetratin, with respect to increasing transcorneal permeability of DSP in a rapid ex-vivo porcine corneal assay over 60 min. The transcorneal apparent permeability coefficients (Papp) for diffusion of pAc, and fluorescein isothiocyanate (FITC) conjugated TAT and penetratin were up to 5 times higher (p < 0.001), when compared to controls. When pAc was used in formulation with DSP, an almost 5-fold significant increase was observed in Papp of DSP across the cornea (p = 0.0130), a significant 6-fold increase with TAT (p = 0.0377), and almost 7-fold mean increase with penetratin (p = 0.9540). Furthermore, we investigated whether the PEAs caused any irreversible damage to the barrier integrity of the corneal epithelium by measuring transepithelial electrical resistance (TEER) and immunostaining of tight junction proteins using zonula occludens-1 (ZO-1) and occludin antibodies. There was no damage or structural toxicity, and the barrier integrity was preserved after PEA application. Finally, an in-vitro cytotoxicity assessment of all PEAs in human retinal pigment epithelium cells (ARPE-19) demonstrated that all PEAs were very well-tolerated, with IC50 values of 64.79 mM for pAc and 1335.45 µM and 87.26 µM for TAT and penetratin, respectively. Our results suggest that this drug delivery technology could potentially be used to achieve a significantly higher intraocular therapeutic bioavailability after topical eye drop administration, than currently afforded
dc.description.sponsorshipThis work was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie-Skłodowska-Curie Actions grant agreement N ◦ 813440 (ORBITAL– Ocular Research by Integrated Training And Learning). Francisco Fernandez-Trillo thanks the University of Birmingham for the John Evans Fellowship, and the Spanish Ministerio de Educaci´ on, Cultura y Deporte for a Beatriz Galindo Award [BG20/00213]. Thomas Leigh acknowledges financial support from the Engineering and Physical Sciences Research Council (EPSRC) through a studentship from the Centre for Doctoral Training in Physical Sciences for Health (EP/L016346/1). Francisco Fernandez- Trillo and Richard Blanch thank the University of Birmingham and the Wellcome Trust for financial support. The funders had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
dc.identifier.citationAbhinav Thareja, Thomas Leigh, Jenni J. Hakkarainen, Helen Hughes, Carmen Alvarez-Lorenzo, Francisco Fernandez-Trillo, Richard J. Blanch, Zubair Ahmed, Improving corneal permeability of dexamethasone using penetration enhancing agents: First step towards achieving topical drug delivery to the retina, International Journal of Pharmaceutics, Volume 660, 2024, 124305, ISSN 0378-5173, https://doi.org/10.1016/j.ijpharm.2024.124305.
dc.identifier.doi10.1016/j.ijpharm.2024.124305
dc.identifier.issn0378-5173
dc.identifier.urihttps://hdl.handle.net/2183/50306
dc.language.isoeng
dc.publisherElsevier
dc.relation.urihttps://doi.org/10.1016/j.ijpharm.2024.124305
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectTopical ocular drug delivery
dc.subjectCornea
dc.subjectPenetration enhancing agents
dc.subjectDexamethasone sodium-phosphate
dc.subjectPosterior ocular segment
dc.subjectCell penetrating peptides
dc.titleImproving Corneal Permeability of Dexamethasone Using Penetration Enhancing Agents: First Step Towards Achieving Topical Drug Delivery to the Retina
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication70a74a46-7cea-40e2-85ef-e99554e97bbe
relation.isAuthorOfPublication.latestForDiscovery70a74a46-7cea-40e2-85ef-e99554e97bbe

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
FernandezTrillo_Paco_2024_Improving_corneal_permeability_of_dexamethasone.pdf
Size:
2.09 MB
Format:
Adobe Portable Document Format